Profil
Dr. Campbell joined Sofinnova Ventures in 2004.
Previously, Dr. Campbell worked for BA Venture Partners, where she focused on mid-stage investment opportunities in drug discovery and product-based companies, and Burrill & Company, a life science merchant banking firm focusing on biotechnology venture capital.
Prior to joining the venture community, Dr. Campbell held both business development and scientific roles at Genentech.
She developed strategic partnerships with Actelion and Gene Logic, among others, and was a member of the Cardiovascular Therapeutic Area Team which was responsible for the strategic vision of that franchise.
She initially joined Genentech as an immunologist in the research department.
Dr. Campbell received her Ph.D.
in Molecular and Cellular Immunology from Mount Sinai Medical Center, during which she was a recipient of the American Gastroenterology Association’s Outstanding Research Award.
She completed her MS in Medical Sciences from the Mount Sinai School of Medicine, and received her BS in Human Biology from the University of Guelph in Ontario, Canada, where she was awarded the Dean’s Scholarship for Academic Excellence.
Anciens postes connus de Nicola Campbell
| Sociétés | Poste | Fin |
|---|---|---|
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 16/06/2008 |
Alvine Pharmaceuticals, Inc.
 Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Directeur/Membre du Conseil | - |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
| MARINUS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Directeur/Membre du Conseil | - |
Formation de Nicola Campbell
| University of Guelph | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Scale Management LLC
 Scale Management LLC Investment ManagersFinance Scale Management LLC (Scale Management) is a venture capital firm founded in 1995 by Kate D. Mitchell and Anchie Y. Kuo. The firm is headquartered in Foster City, California. | Finance |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Health Technology |
Alvine Pharmaceuticals, Inc.
Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Health Technology |
